Aligos Therapeutics (ALGS) Expected to Post Earnings on Thursday

Aligos Therapeutics (NASDAQ:ALGS) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Aligos Therapeutics to post earnings of ($2.44) per share and revenue of $4.85 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.95. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. The firm had revenue of $27.78 million for the quarter, compared to the consensus estimate of $24.68 million. On average, analysts expect Aligos Therapeutics to post ($6.81) EPS for the current fiscal year and ($5.39) EPS for the next fiscal year.

Aligos Therapeutics Stock Performance

Shares of ALGS stock opened at $4.60 on Tuesday. Aligos Therapeutics has a 52-week low of $3.98 and a 52-week high of $13.69. The firm has a market capitalization of $28.73 million, a PE ratio of -0.63 and a beta of 2.36. The stock has a fifty day simple moving average of $5.52 and a two-hundred day simple moving average of $6.25.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ALGS shares. Weiss Ratings lowered Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. Finally, Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.